Clinical Manifestations of Impaired GnRH Neuron Development and FunctionKim H.-G.a · Bhagavath B.b · Layman L.C.a
aSection of Reproductive Endocrinology, Infertility, and Genetics, Department of Obstetrics and Gynecology, Reproductive Medicine Program, Developmental Neurobiology Program, Institute of Molecular Medicine and Genetics, Neuroscience Program, Medical College of Georgia, Augusta, Ga., and bDivision of Reproductive Endocrinology and Infertility, Women and Infants’ Hospital of Rhode Island, Brown University, Providence, R.I., USA
Lawrence C. Layman, MD
Section of Reproductive Endocrinology, Infertility, and Genetics Department of Obstetrics and Gynecology, The Medical College of Georgia
1120 15th Street, Augusta, GA 30912-3360 (USA)
Tel. +1 706 721 3832, Fax +1 706 7216830, E-Mail firstname.lastname@example.org
Do you have an account?
Gonadotropin-releasing hormone (GnRH) and olfactory neurons migrate together in embryologic development, and disruption of this process causes idiopathic hypogonadotropic hypogonadism (IHH) with anosmia (Kallmann syndrome (KS)). Patients with IHH/KS generally manifest irreversible pubertal delay and subsequent infertility due to deficient pituitary gonadotropins or GnRH. The molecular basis of IHH/KS includes genes that: (1) regulate GnRH and olfactory neuron migration; (2) control the synthesis or secretion of GnRH; (3) disrupt GnRH action upon pituitary gonadotropes, or (4) interfere with pituitary gonadotropin synthesis or secretion. KS patients may also have midline facial defects indicating the diverse developmental functions of genes involved. Most causative genes cause either normosmic IHH or KS except FGFR1, which may cause either phenotype. Recently, several balanced chromosomal translocations have been identified in IHH/KS patients, which could lead to the identification of new disease-producing genes. Although there are two cases reported who have digenic disease, this awaits confirmation in future larger studies. The challenge will be to determine the importance of these genes in the 10–15% of couples with normal puberty who have infertility.
© 2008 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.